About Alopecia Drugs
Alopecia is a loss of hair and can occur at any age across the genders. The exact cause of this disorder is unknown, but many factors are assumed to be responsible for developing alopecia. Few of the primary ones are a sedentary lifestyle, unhealthy diets, and side effects of certain medical treatments. Moreover, hormonal imbalance and aging increase the probability of developing a chronic disease like cancer, arthritis, depression, and hypertension, which would also lead to hair loss, especially among middle-to-late-aged people.
Technavio’s analysts forecast the global alopecia drugs market to grow at a CAGR of 5.02% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global alopecia drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of alopecia drugs.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Alopecia Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• GlaxoSmithKline
• Johnson & Johnson
• Merck
Other prominent vendors
• Aclaris Therapeutics
• Actelion Pharmaceuticals
• Almirall
• AndroScience
• Anterios
• Aqua Pharmaceuticals
• Astellas Pharma
• Bayer HealthCare
• BERG Health
• BiologicsMD
• BioPharmX
• Celtaxsys
• Cipher Pharmaceuticals
• Concert Pharmaceuticals
• Cosmo Pharmaceuticals
• Dermira
• Elorac
• F. Hoffmann-La Roche
• Foamix
• Guthy-Renker
• Helix BioMedix
• Hygeia Therapeutics
• Hyundai Pharm
• Incyte
• Kasiak Research
• Kythera Biopharmaceuticals
• Mylan
• NovaLead Pharma
• Novan
• Oculus Innovative Sciences
• Paratek Pharmaceuticals
• Photocure
• Polichem
• Promius Pharma
• Ranbaxy Laboratories
• Reckitt Benckiser
• Regience
• Samumed
• RepliCel
• Skinvisible Pharmaceuticals
• Teva Pharmaceutical
• Versapharm
• XBiotech
Market driver
• Popularity of off-label and OTC drugs
• For a full, detailed list, view our report
Market challenge
• Limited availability of approved drugs
• For a full, detailed list, view our report
Market trend
• Emergence of laser technology and platelet-rich plasma (PRP) therapy
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Overview: Alopecia
• Causes of hair loss
• Hair loss: Symptoms and treatment
PART 06: Pipeline portfolio
PART 07: Market landscape
• Market overview
• Five forces analysis
PART 08: Key buying criteria
PART 09: Market segmentation by ROA
• Global topical alopecia drugs market
• Global oral alopecia drugs market
• Global injectable alopecia drugs market
PART 10: Market segmentation by gender
PART 11: Geographical segmentation
• Alopecia drugs market in Americas
• Alopecia drugs market in EMEA
• Alopecia drugs market in APAC
PART 12: Market drivers
• Lifestyle changes
• Popularity of off-label and OTC drugs
• High uptake of approved therapies
PART 13: Impact of drivers
PART 14: Market challenges
• Poor patient adherence
• Preference for alternative therapies
• Limited approved therapies
PART 15: Impact of drivers and challenges
PART 16: Market trends
• Focus on regenerative medicines
• Emergence of laser technology and PRP therapy
• Launch of new products
PART 17: Vendor landscape
• Competitive scenario
• Other prominent vendors
PART 18: Key vendor analysis
• GlaxoSmithKline
• Johnson & Johnson
• Merck
PART 19: Appendix
• List of abbreviations
PART 20: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Major types of alopecia
Exhibit 03: Major factors responsible for hair loss
Exhibit 04: Symptoms and treatment of hair loss
Exhibit 05: Pipeline analysis of major companies for global alopecia drugs market
Exhibit 06: Share of pipeline molecules in global alopecia drugs market
Exhibit 07: Pipeline analysis of major companies for global alopecia drugs market
Exhibit 08: Market snapshot: Global alopecia drugs market
Exhibit 09: Incidence rates of alopecia areata 2015 (in percentage of population)
Exhibit 10: Possibility of hair loss (men) grows with age 2015
Exhibit 11: Distribution of population aged 60 years and over (millions)
Exhibit 12: Factors influencing the global alopecia drugs market 2015
Exhibit 13: Global alopecia drugs market snapshot: Developed and emerging markets 2015
Exhibit 14: Global alopecia drugs market 2015-2020 ($ billions)
Exhibit 15: Hair loss treatment cost
Exhibit 16: Key strategies in global alopecia drugs market
Exhibit 17: Five forces analysis
Exhibit 18: Key buying criteria for alopecia drugs market
Exhibit 19: Key buying criteria for global alopecia drugs market 2015
Exhibit 20: Impact of key customer segments on global alopecia drugs market 2015
Exhibit 21: Global alopecia drugs segmentation market by route of administration
Exhibit 22: Global alopecia drugs market: Segmentation by type 2015-2020
Exhibit 23: Global alopecia drugs market segmentation: Growth cycle analysis
Exhibit 24: Global topical alopecia drugs market 2015-2020 ($ billions)
Exhibit 25: Global oral alopecia drugs market 2015-2020 ($ millions)
Exhibit 26: Global injectable alopecia drugs market 2015-2020 ($ millions)
Exhibit 27: Snapshot of global alopecia drugs market by gender
Exhibit 28: Willingness toward treatment among individuals affected with hair loss
Exhibit 29: Snapshot of global alopecia drugs market by geography
Exhibit 30: Global alopecia drugs market: Country analysis based on revenue and growth rate
Exhibit 31: Global alopecia drugs market segmentation by geography 2015-2020 ($ millions)
Exhibit 32: Overview of alopecia drugs market in Americas
Exhibit 33: Prevalence of alopecia areata in Americas 2015 (millions)
Exhibit 34: Alopecia drugs market in Americas 2015-2020 ($ billions)
Exhibit 35: Overview of alopecia drugs market in EMEA
Exhibit 36: Alopecia drugs market in EMEA 2015-2020 ($ millions)
Exhibit 37: Prevalence of alopecia areata in EMEA 2015 (millions)
Exhibit 38: Overview of alopecia drugs market in APAC
Exhibit 39: Alopecia drugs market in APAC 2015-2020 ($ millions)
Exhibit 40: Prevalence of alopecia areata in APAC 2015 (millions)
Exhibit 41: Impact of alcohol on hair loss
Exhibit 42: Impact of stress on hair loss
Exhibit 43: Off-label usage: Tagamet (cimetidine) for the treatment of alopecia
Exhibit 44: Few of the popular OTC drugs used for the treatment of alopecia
Exhibit 45: Market scenario of leading Alopecia drugs: Present and future
Exhibit 46: Impact of drivers
Exhibit 47: Side effects associated with approved therapies
Exhibit 48: Hair loss surgeries performed in 2015
Exhibit 49: Number of hair restoration procedures worldwide 2015
Exhibit 50: Impact of drivers and challenges
Exhibit 51: Overview of alopecia in regenerative medicine market
Exhibit 52: Variety of growth factors released from PRP therapy
Exhibit 53: List of pipeline candidates for alopecia treatment
Exhibit 54: Competitive structure analysis of global alopecia drugs market 2015
Exhibit 55: Performance/initiatives of existing and upcoming vendors in global alopecia drugs market
Exhibit 56: Geographical presence of key vendors
Exhibit 57: GlaxoSmithKline: Profile
Exhibit 58: GlaxoSmithKline: Strength assessment
Exhibit 59: GlaxoSmithKline: Strategy assessment
Exhibit 60: GlaxoSmithKline: Opportunity assessment
Exhibit 61: Johnson & Johnson: Strength assessment
Exhibit 62: Johnson & Johnson: Strategy assessment
Exhibit 63: Johnson & Johnson: Opportunity assessment
Exhibit 64: Merck: Strength assessment
Exhibit 65: Merck: Strategy assessment
Exhibit 66: Merck: Opportunity assessment
